Dr. Minna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-645-8600
Summary
- Dr. Minna is Director of the Hamon Center for Therapeutic Oncology Research, and Professor of Internal Medicine and Pharmacology at The University of Texas Southwestern Medical Center (1991-present). He holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research. He graduated from Stanford Medical School (research under Leonard Herzenberg), was a resident at Massachusetts General Hospital, a Research Associate at the NIH (under Dr. Marshal Nirenberg), Chief of the Section of Somatic Cell Genetics, Chief of the NCI-VA and then NCI-Navy Medical Oncology Branches at the National Cancer Institute (1975-1991). His work focuses on understanding the molecular pathogenesis of lung cancer and translating this into the clinic by identifying and targeting acquired lung cancer vulnerabilities. He has trained many investigators in lung cancer research. He has led a joint Lung Cancer NCI Special Program of Research Excellence (SPORE) grant between UTSW and the MD Anderson Cancer Center for 25 years. His publications have an H-Index of 193, and a D-Index of 179 with some 130,000 citations.
Education & Training
National Heart Lung and Blood Institute (NHLBI)Post-Doctoral Fellowship, 1969 - 1973
Massachusetts General HospitalResidency, Internal Medicine, 1967 - 1969
Stanford University School of MedicineClass of 1967
Certifications & Licensure
CA State Medical License 1972 - Present
TX State Medical License 1992 - 2025
DC State Medical License 1974 - 1997
MD State Medical License 1974 - 1995
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member American Association of Physicians, 1991
- Fellow (FASCO) American Society of Clinical Oncologists, 2007
- Elected Member The American Society for Clinical Investigation, 1984
Publications & Presentations
PubMed
- Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair.Jui-Chung Chiang, Zengfu Shang, Tracy Rosales, Ling Cai, Wei-Min Chen
Science Advances. 2025-03-14 - KSR2 promotes self-renewal and clonogenicity of small-cell lung carcinoma.Dianna H Huisman, Deepan Chatterjee, Robert A Svoboda, Heidi M Vieira, Abbie S Ireland
Molecular Cancer Research. 2025-03-10 - High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non-Small Cell Lung Cancer in Patients.Ling Cai, Nia G Hammond, Alpaslan Tasdogan, Massar Alsamraae, Chendong Yang
Cancer Discovery. 2025-02-17
Journal Articles
- Retraction Notice to “Sun Exposure Related Methylation in Malignant and Non-Malignant Skin Lesions” [Cancer Letters 245/1-2 (2007) 112-120]John D Minna, Cancer Letters
- Inhibition of thioredoxin/thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione HomeostasisJohn V Heymach, Stephen G Swisher, Jack A Roth, John D Minna, Clinical Cancer Research
- JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung CancerJohn D Minna, Jonathan M Kurie, J Jack Lee, Vassiliki A Papadimitrakopoulou, Neda Kalhor, Roy S Herbst, Clinical Cancer Research
- Join now to see all
Press Mentions
Children’s Research Institute at UT Southwestern Scientists Identify Feature of Aggressive Non-Small Cell Lung CancerFebruary 19th, 2025- Antibody Designed to Fight Immunotherapy-Resistant CancersFebruary 14th, 2025
- National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney CancerSeptember 19th, 2022
- Join now to see all
Grant Support
- Coordinating center for the NCI small cell lung cancer research consortiumSLOAN-KETTERING INST CAN RESEARCH2022–2027
- Cancer Center Support Grant (CCSG)National Cancer Institute2021–2026
- Vulnerability of SARS-CoV-2 Infection in Lung Cancer Based on Serological Antibody AnalysesNational Cancer Institute2020–2025
- Coordinating Center for Small Cell Lung Cancer U01National Cancer Institute2017–2025
- Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
- Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
- Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
- Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
- Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
- Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
- Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
- The University of Texas SPORE (Special Program of Research Excellence) in Lung Cancer Targeting Lung Cancer VulnerabilitiesNational Cancer Institute1996–2025
- Natural Products with Selective Cytoxicity to Non-Small Cell LungNational Cancer Institute2018–2023
- Developing ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancerNational Cancer Institute2017–2022
- Molecular Pathology Of Lung CancerNational Cancer Institute2005
- Characterization Of Human 3P Recessive OncogenesNational Cancer Institute2001–2004
- Human 3P Recessive OncogenesNational Cancer Institute1996–1999
- Spore In Lung CancerNational Cancer Institute1992–1994
Professional Memberships
- Fellow
- Member
- Member
- Fellow
- Member
- Member
- American Federation of Clinical Research (AFCR)Member
- International Association for the Study of Lung Cancer (IASLC)Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
